Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous tislelizumab plus chemotherapy in first-line advanced gastric or gastroesophageal junction adenocarcinoma
2025-522862-58-00Phase 3Authorised
- Sponsor
- BeOne Medicines
- Start
- Jan 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of odronextamab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by BeOne Medicines. Primary endpoints: Model-predicted trough serum concentration at steady state and Model-predicted AUC over 21 days of Cycle 1. Planned start Jan 2026; status: authorised.
02
Drugs
odronextamab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2025-522862-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522862-58-00.